Mike Tentilucci joined Ropes & Gray's corporate department in 2021. Mike focuses his practice on representing public companies and investment banks in connection with capital markets transactions and compliance with securities laws and stock exchange rules and regulations, as well as mergers & acquisitions, other strategic transactions and general corporate governance matters.

Experience

Mike has represented:

  • TransMedics Group, Inc. in its acquisition of organ support and heart preservation transport system assets from Bridge to Life Ltd. 
  • the lead underwriters in a $500 million follow-on equity offering for Madrigal Pharmaceuticals, Inc. 
  • Cyteir Therapeutics, Inc. in its initial public offering, as well as ongoing disclosure and governance matters.
  • RVL Pharmaceuticals plc in equity offerings, as well as ongoing disclosure and governance matters.
  • Novavax, Inc. in equity offerings, as well as ongoing disclosure and governance matters.
  • the lead underwriters in the initial public offering of byNordic Acquisition Corporation.
  • the lead underwriters in the initial public offering of CIIG Capital Partners II, Inc.
  • the lead underwriters in the initial public offering of Tio Tech A.
  • an investment manager in the Series B financing for Breeze Aviation Group, Inc.
  • Pfizer Inc. in its acquisition of Trillium Therapeutics.
  • Acceleron Pharma Inc. in its sale to Merck.